B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases

Journal of Autoimmunity

Volumn 43, Issue , 2013, Pages 55-59

  Sangle, Shirish R ^a   Lutalo, Pamela M K ^a   Davies, Rachel J ^a   Khamashta, Munther A ^a   D'Cruz, David P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Autoimmune diseases; B cells; Systemic lupus erythematosus; Systemic vasculitis

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; RAMIPRIL; RITUXIMAB; STEROID;

ADULT; ADVERSE OUTCOME; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIRTH WEIGHT; CLINICAL ARTICLE; DISEASE DURATION; ESOPHAGUS ATRESIA; FEMALE; GESTATIONAL AGE; HUMAN; HUMORAL IMMUNITY; IMMUNOTHERAPY; INFORMED CONSENT; LOW BIRTH WEIGHT; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL DOCUMENTATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; THIRD TRIMESTER PREGNANCY;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; ESOPHAGEAL ATRESIA; FEMALE; HUMANS; INFANT, NEWBORN; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LYMPHOCYTE DEPLETION; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; WEGENER GRANULOMATOSIS;

EID: 84878354504     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.03.001     Document Type: Article

References (42)

1. Ostensen M., Khamashta M., Lockshin M., Parke A., Brucato A., Carp H., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006, 8:209.
2. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:17-25.
3. Leavitt R.Y., Fauci A.S., Bloch D.A., Michel B.A., Hunder G.G., Arend W.P. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990, 33:1101-1107.
4. Stone J.H., Hoffman G.S., Merkel P.A., Min Y.I., Uhlfelder M.L., Hellmann D.B., et al. Adisease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001, 44:912-920.
5. Yee C.S., Farewell V., Isenberg D.A., Prabu A., Sokoll K., Teh L.S., et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006, 54:3300-3305.
6. Weiner G.J. Rituximab: mechanism of action. Semin Hematol 2010, 47:115-123.
7. Smyth A., Oliveira Lahr B., Bailey K., Norby S., Garovic V. Asystematic review and meta analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010, 5:2060-2068.
8. Bramham K., Soh M.C., Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. Lupus 2012, 21:1271-1283.
9. Andreoli L., Fredi M., Nalli C., Reggia R., Lojacono A., Motta M., et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. JAutoimmun 2012, 38:J197-J208.
10. Karim M.Y., D'Cruz D.P. Practical management of lupus nephritis in pregnancy and the puerperium. Expert Rev Clin Pharmacol 2010, 3:777-784.
11. Hejaili F.F., Moist L.M., Clark W.F. Treatment of lupus nephritis. Drugs 2003, 63:257-274.
12. Parke A., West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. JRheumatol 1996 Oct, 23(10):1715-1718.
13. Costedoat-Chalumeau N., Amoura Z., Duhaut P., Huong D.L., Sebbough D., Wechsler B. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003 Nov, 48:3207-3211.
14. Clowse M.E., Magder L., Witter F., Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006 Nov, 54:3640-3647.
15. George K.Bertsias, Maria Tektonidou, Zahir Amoura, Martin Aringer, Ingeborg Bajema, Jo H.M.Berden Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012, 71:1771-1782.
16. Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012, 64:1215-1226.
17. Diaz-Lagares C., Croca S., Sangle S., Vital E.M., Catapano F., Martinez-Berriotxoa A., et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012, 11:357-364.
18. Pepper R., Griffith M., Kirwan C., Levy J., Taube D., Pusey C., et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 2009, 24:3717-3723.
19. Lightstone L. The landscape after LUNAR: rituximab's crater-filled path. Arthritis Rheum 2012, 64:962-965.
20. Ostensen M., Förger F. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol 2011, 23:293-298.
21. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003, 28:3365-3369.
22. Malek A. Exvivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine 2003, 21:3362-3364.
23. Schroder C., Azimzadeh A.M., Wu G., Price J.O., Atkinson J.B., Pierson R.N. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol 2003, 12:19-28.
24. Vinet E., Pineau C., Gordon C.E., Clarke A., Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Care Res 2009, 61:587-589.
25. Klink D.T., van Elburg R.M., Schreurs M.W., van Well G.T. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008, 2008:271363.
26. Kimby E., Sverrisdottir A., Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 2004, 72:2.
27. Decker M., Rothermundt C., Hollander G., Tichelli A., Rochlitz C. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 2006, 7:693-694.
28. Ponte P., Lopes M.J. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. JAm Acad Dermatol 2010, 63:355-356.
29. Rey J., Coso D., Roger V., Bouayed N., Belmecheri N., Ivanov V., et al. Rituximab combined with chemotherapy for lymphoma during pregnancy. Leuk Res 2009, 33:e8-e9.
30. Ostensen M., Lockshin M., Doria A., Valesini G., Meroni P., Gordon C., et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008, 47(Suppl. 3):iii28-iii31.
31. Ng C.T., O'Neil M., Walsh D., Walsh T., Veale D.J. Successful pregnancy after rituximab in a women with recurrent invitro fertilisation failures and anti-phospholipid antibody positive. Ir J Med Sci 2009, 178:531-533.
32. Fischer-Betz R.E., Schneider M. Biologics during pregnancy and breast-feeding. ZRheumatol 2010, 69:780-787.
33. Gall B., Yee A., Berry B., Birchman D., Hayashi A., Dansereau J., et al. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. Obstet Gynaecol Can 2010, 32:1167-1171.
34. Chakravaty E., Murray E., Kelman A., Farmer P. Pregnancy outcomes in patients with autoimmune diseases treated with Rituximab. Blood 2011, 117:1499-1506.
35. Furst D.E., Keystone E.C., Braun J., Breedveld F.C., Burmester G.R., De Benedetti F., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2012, 71(suppl2):i2-i45.
36. Ostensen M., Von Esebeck M., Villiger P.M. Therapy with immunosuppressive drugs and biologic agents and use of contraception in patients with rheumatic disease. JRheumatol 2007, 34:1266-1269.
37. Ton E., Tekstra J., Hellmann P.M., Nuver-Zwart I.H., Bijlsma J.W. Safety of rituximab therapy during twins' pregnancy. Rheumatology (Oxford) 2011, 50:806-808.
38. Pellkofer H.L., Suessmair C., Schulze A., Hohlfeld R., Kuempfel T. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 2009, 15:1006-1008.
39. Ojeda-Uribe M., Gilliot C., Jung G., Drenou B., Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. JPerinatol 2006, 26:252-255.
40. Chambers S.A., Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 2005, 14:210-214.
41. Baer A.N., Witter F.R., Petri M. Lupus and pregnancy. Obstet Gynecol Surv 2011, 66:639-653.
42. Pagnoux C. Pregnancy and vasculitides. Presse Med 2008, 37:1657-1665.